Empagliflozin Attenuates Neointima Formation After Arterial Injury and Inhibits Smooth Muscle Cell Proliferation and

Gwo-Jyh Chang1,2, Wei-Jan Chen2, Yu-Juei Hsu3

  • 1Graduate Institute of Clinical Medicinal Sciences Chang-Gung University College of Medicine Tao-Yuan Taiwan.

Abstract

Insights

Empagliflozin inhibits neointima formation by suppressing platelet-derived growth factor (PDGF) signaling, independent of SGLT2. This mechanism offers new insights into preventing vascular stenosis disorders.

Area of Science:

  • Cardiovascular Research
  • Pharmacology
  • Cell Biology

Background:

  • Sodium-glucose cotransporter 2 (SGLT2) inhibitors are known to reduce cardiovascular events.
  • The exact mechanisms underlying these benefits, beyond glycemic control, require further elucidation.
  • Platelet-derived growth factor (PDGF)-related signaling is implicated in vascular remodeling processes.

Purpose of the Study:

  • To investigate the role of PDGF-related signaling in empagliflozin's effects on neointima formation.
  • To determine if empagliflozin's vascular effects are dependent on SGLT2 expression or glycemic control.

Main Methods:

  • Adult male Wistar rats underwent carotid artery balloon injury.
  • Empagliflozin was administered orally before and after injury.
  • In vitro studies assessed empagliflozin's impact on vascular smooth muscle cell (VSMC) proliferation and migration.
  • PDGF signaling pathways (PDGF receptor β, Akt, STAT3 phosphorylation) were analyzed.

Main Results:

  • Empagliflozin significantly reduced neointima formation following balloon injury.
  • Empagliflozin inhibited PDGF-BB-induced VSMC proliferation and migration in vitro.
  • Empagliflozin suppressed PDGF-related signaling pathways.
  • SGLT2 was undetectable in rat VSMCs, and its silencing did not affect empagliflozin's actions.

Conclusions:

  • Empagliflozin's beneficial effects on neointima formation and VSMC function are mediated by suppressing PDGF-related signaling.
  • These vascular protective effects are independent of SGLT2 and glycemic control.
  • This study reveals a novel mechanism for empagliflozin in preventing vascular stenosis.

Related Concept Videos

Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
172
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
2.5K
Intracellular Signaling Affects Focal Adhesions01:17

Intracellular Signaling Affects Focal Adhesions

Integrins act both as extracellular input receivers and as intracellular processing activators. As their name suggests, integrins are entirely integrated into the membrane structure. Their hydrophobic membrane-spanning regions interact with the phospholipid bilayer's hydrophobic region. These membrane receptors provide extracellular attachment sites for effectors like hormones and growth factors. They activate intracellular response cascades when their effectors are bound and active.
Some...
2.6K